Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-07-06 am EDT
3624.00 JPY   +1.48%
06/29CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for interim dividend
FA
06/27CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
06/30/2022 07/01/2022 07/04/2022 07/05/2022 07/06/2022 Date
3470(c) 3476(c) 3529(c) 3571(c) 3624(c) Last
3 418 100 2 828 500 1 620 600 1 399 000 2 598 000 Volume
-1.64% +0.17% +1.52% +1.19% +1.48% Change
More quotes
Estimated financial data (e)
Sales 2022 1 186 B 8 732 M 8 732 M
Net income 2022 341 B 2 511 M 2 511 M
Net cash position 2022 516 B 3 801 M 3 801 M
P/E ratio 2022 17,5x
Yield 2022 2,15%
Sales 2023 1 034 B 7 612 M 7 612 M
Net income 2023 313 B 2 304 M 2 304 M
Net cash position 2023 759 B 5 591 M 5 591 M
P/E ratio 2023 19,0x
Yield 2023 2,28%
Capitalization 5 960 B 43 889 M 43 889 M
EV / Sales 2022 4,59x
EV / Sales 2023 5,03x
Nbr of Employees 7 664
Free-Float 37,8%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
Read more
Sector
Pharmaceuticals
Calendar
07/21 | 04:00amEarnings Release
More about the company
Ratings of Chugai Pharmaceutical Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD
06/29CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for interim dividend
FA
06/27CHUGAI PHARMACEUTICAL : Script (including Q&A)
PU
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo..
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemop..
MT
06/20Roche's Chugai, Zenyaku Kogyo Win Japanese Nod For Rituxan Drug Against Neuromyelitis O..
MT
06/20Roche's Chugai Pharmaceutical Wins Japanese Regulatory Nod For Changes To Leukemia, Ova..
MT
06/20CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Hemlibra for Additional Indication..
PU
06/20CHUGAI PHARMACEUTICAL : Obtains Partial Change Approval for Neutrogin and Avastin Based on..
PU
06/20CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention ..
PU
06/10Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pa..
MT
06/10Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Ni..
MT
06/09CHUGAI PHARMACEUTICAL : Notice of Filing an Appeal in Patent Infringement Lawsuit concerni..
PU
06/08Chugai Receives DX Grand Prix 2022 Awards in Digital Transformation Stocks (DX Stocks) ..
AQ
06/07Chugai Supports the Japan Climate Initiative's Calling to Raise Renewable Energy Target
AQ
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD
06/20L'Hemlibra de Roche reçoit l'approbation du Japon pour une indication supplémentaire de..
06/20Chugai et Zenyaku Kogyo (Roche) obtiennent le feu vert japonais pour le médicament Ritu..
06/20Chugai Pharmaceutical, filiale de Roche, obtient le feu vert des autorités japonaises p..
06/20ROCHE : extension d'indication pour l'Hemlibra (hémophilie) au Japon
06/20Roche-Tochter Chugai erhält Zulassungserweiterung für Blutermittel Hemlibra
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Analysis
TIMELINE-Toshiba's lurch from crisis to crisis since 2015
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 624,00 JPY
Average target price 4 577,69 JPY
Spread / Average Target 26,3%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-4.39%43 255
JOHNSON & JOHNSON4.94%468 758
ELI LILLY AND COMPANY17.55%294 514
PFIZER, INC.-11.41%289 747
ABBVIE INC.13.69%272 011
ROCHE HOLDING AG-15.85%269 131